Showing results (131-140 of 177) with videos related to

Sort By:
Pageof 18
The Lancet. Neurology|February 16, 2024
Safety and efficacy of atogepant for the preventive treatment of episodic migraine in adults for whom conventional oral preventive treatments have failed (ELEVATE): a randomised, placebo-controlled, phase 3b trialCristina Tassorelli, Krisztián Nagy, Patricia Pozo-Rosich, et al.
Headache|February 20, 2020
Ubrogepant, an Acute Treatment for Migraine, Improved Patient-Reported Functional Disability and Satisfaction in 2 Single-Attack Phase 3 Randomized Trials, ACHIEVE I and IIDavid W Dodick, Richard B Lipton, Jessica Ailani, et al.
Cephalalgia : an International Journal of Headache|November 26, 2020
Time course of efficacy of ubrogepant for the acute treatment of migraine: Clinical implicationsPeter J Goadsby, Andrew M Blumenfeld, Richard B Lipton, et al.
Neurology|May 1, 1997
Oral phenylalanine loading in dopa-responsive dystonia: a possible diagnostic testK Hyland, J S Fryburg, W G Wilson, et al.
Cephalalgia : an International Journal of Headache|September 21, 2019
Safety and tolerability of ubrogepant following intermittent, high-frequency dosing: Randomized, placebo-controlled trial in healthy adultsPeter J Goadsby, Stewart J Tepper, Paul B Watkins, et al.
Lancet (London, England)|November 18, 2023
Ubrogepant for the treatment of migraine attacks during the prodrome: a phase 3, multicentre, randomised, double-blind, placebo-controlled, crossover trial in the USADavid W Dodick, Peter J Goadsby, Todd J Schwedt, et al.
Neurology|August 17, 2022
Efficacy of Ubrogepant in the Acute Treatment of Migraine With Mild Pain vs Moderate or Severe PainRichard B Lipton, David W Dodick, Peter J Goadsby, et al.
Headache|July 3, 2026
Weight loss with atogepant in the long-term treatment of migraine: An interim analysis of a safety endpoint from a phase 3, multicenter, open-label, 156-week extension studyDale S Bond, Jonathan H Smith, Alexandra Sinclair, et al.
The Journal of Physical Chemistry. A|August 7, 2008
Ultrafast spectroscopy of the uranium(IV) and thorium(IV) bis(ketimide) complexes (C5Me5)2An[-N=C(Ph)(CH2Ph)]2 (An = Th, U)David J Hilton, Rohit P Prasankumar, Eric J Schelter, et al.
Nature Medicine|May 12, 2025
Ubrogepant for the treatment of migraine prodromal symptoms: an exploratory analysis from the randomized phase 3 PRODROME trialPeter J Goadsby, Jessica Ailani, David W Dodick, et al.
Pageof 18